B. Nadres

发表

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

E. Collisson, F. Kaye, I. Yeh, 2018 .

Title: Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

E. Collisson, F. Kaye, Wei Wu, 2019 .

Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).

Jeffrey W. Clark, A. Zhu, D. Ryan, 2019, Journal of Clinical Oncology.

Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).

Jeffrey W. Clark, K. Lillemoe, A. Zhu, 2018 .

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

W. Hahn, G. Getz, A. Iafrate, 2019, Cancer discovery.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Nir Hacohen, Keren Yizhak, Yunxin J. Jiao, 2017, Nature Communications.

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

E. Collisson, F. Kaye, I. Yeh, 2019, Clinical Cancer Research.

Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation

E. Collisson, F. Kaye, I. Yeh, 2018, bioRxiv.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Nicholas D. Camarda, Jeffrey W. Miller, W. Hahn, 2018, Cancer discovery.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

S. Digumarthy, A. Iafrate, L. Sequist, 2018, JCO precision oncology.

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Jeffrey W. Clark, A. Iafrate, D. Dias-Santagata, 2020, Clinical Cancer Research.

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Jeffrey W. Clark, T. Golub, G. Getz, 2019, Nature Medicine.

Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer

Jeffrey W. Clark, A. Zhu, J. Lennerz, 2021, JCO precision oncology.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Jeffrey W. Clark, A. Iafrate, E. V. Van Allen, 2018, Cancer discovery.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

R. Sullivan, K. Flaherty, Dennie T. Frederick, 2018, Oncoimmunology.

Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients.

Jeffrey W. Clark, A. Bardelli, A. Zhu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.